Literature DB >> 18622386

N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas.

Jean-François Mosnier1, Christine Kandel, Dominique Cazals-Hatem, Chantal Bou-Hanna, Jérome Gournay, Anne Jarry, Christian L Laboisse.   

Abstract

As a definite immunoprofile of this tumor is missing, the histopathologic diagnosis of intrahepatic cholangiocarcinoma is difficult. The aim of this study was to explore E- and N-cadherin expressions in intrahepatic bile duct tumors, and to determine their potential interest in differential diagnosis. Normal liver tissue, 5 cirrhosis with ductular reaction, 5 focal nodular hyperplasia, 5 bile duct hamartomas, 5 bile duct adenomas, and 45 intrahepatic cholangiocarcinomas from Caucasian patients were studied. Tissue-microarrays including 20 esophageal, 86 gastric, 8 small bowel, 64 colonic, 18 pancreatic, 6 gallbladder, and 7 extrahepatic biliary tract adenocarcinomas, 22 hepatocellular carcinomas, and normal tissues were constructed. Immunohistochemistry was performed using E-cadherin, N-cadherin, NCAM, Hep Par1, and cytokeratins 7, 19 and 20. Immunoblot analysis of frozen liver tissues was performed to control the specificity of E- and N-cadherin antibodies used. In normal liver, epithelial cells of intrahepatic bile ducts, whatever their caliber, as well as hepatocytes, coexpressed E- and N-cadherins at their plasma membranes. In cirrhosis, ductular reactions completely expressed E- and N-cadherins. All the benign lesions and 30 of the 45 intrahepatic cholangiocarcinomas (23/29 peripheral and 7/16 hilar) also expressed N-cadherin. E-cadherin was detected in all the lesions. The expression of N-cadherin at the plasma membrane of tumor cells was significantly more frequent in peripheral than in hilar intrahepatic cholangiocarcinomas (P=0.003). Among noncholangiocarcinomas, only 1% gastric and 66% gallbladder adenocarcinomas and all the hepatocellular carcinomas expressed N-cadherin at the membrane of tumor cells. Finally, for the diagnosis of intrahepatic cholangiocarcinomas, the specificity value of membranous expression of N-cadherin was 88%, whereas that of the combination cytokeratin 7/membranous N-cadherin was 98%. In the gastrointestinal and liver tract, membranous N-cadherin is restricted to the hepatocytes and intrahepatic biliary cells. In combination with cytokeratin 7 and Hep Par1, N-cadherin is a reliable tool for the histopathological diagnosis of primary hepatic tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622386     DOI: 10.1038/modpathol.2008.123

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

1.  The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.

Authors:  Jody E Hooper; Terry K Morgan; Markus Grompe; Brett C Sheppard; Megan L Troxell; Christopher L Corless; Philip R Streeter
Journal:  Hum Pathol       Date:  2012-03-09       Impact factor: 3.466

2.  Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes.

Authors:  Branden D Tarlow; Carl Pelz; Willscott E Naugler; Leslie Wakefield; Elizabeth M Wilson; Milton J Finegold; Markus Grompe
Journal:  Cell Stem Cell       Date:  2014-10-09       Impact factor: 24.633

3.  Markers of bile duct tumors.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Alessandra Rando; Mario Uccello; Francesco Basile; Antonio Biondi; Santo Carnazzo; Innocenza Alessandria; Clorinda Mazzarino
Journal:  World J Gastrointest Oncol       Date:  2011-04-15

4.  Expression of hepatocyte markers in mass-forming peripheral and periductal-infiltrating hilar intrahepatic cholangiocarcinomas.

Authors:  Hiroya Iida; Masaki Hata; Ayako Kakuno; Hiroshi Hirano; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Nobuyuki Terada; Chiaki Yasui; Naoki Yamanaka; Keiji Nakasho
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

5.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

6.  Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns.

Authors:  Carlie S Sigel; Esther Drill; Yi Zhou; Olca Basturk; Gokce Askan; Linda M Pak; Efsevia Vakiani; Tao Wang; Thomas Boerner; Richard K G Do; Amber L Simpson; William Jarnagin; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2018-10       Impact factor: 6.394

Review 7.  Hepatitis B virus infection and intrahepatic cholangiocarcinoma.

Authors:  Hua-Bang Zhou; Jing-Yi Hu; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

8.  Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome.

Authors:  Qing-Long Li; Zhu-Lin Yang; Jie-Qiong Liu; Xiong-Ying Miao
Journal:  Pathol Oncol Res       Date:  2011-01-08       Impact factor: 3.201

9.  Derivation and characterization of hepatic progenitor cells from human embryonic stem cells.

Authors:  Dongxin Zhao; Song Chen; Jun Cai; Yushan Guo; Zhihua Song; Jie Che; Chun Liu; Chen Wu; Mingxiao Ding; Hongkui Deng
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

10.  N-cadherin Expression in Testicular Germ Cell and Gonadal Stromal Tumors.

Authors:  Daniel J Heidenberg; Joel H Barton; Denise Young; Michael Grinkemeyer; Isabell A Sesterhenn
Journal:  J Cancer       Date:  2012-09-11       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.